PMID: 9537208Apr 16, 1998Paper

Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a phase I trial

American Journal of Clinical Oncology
A SandlerR Dreicer

Abstract

To determine the maximally tolerated dose of paclitaxel with and without filgrastim (G-CSF) when administered as a 24-hour intravenous infusion after a 120-hour infusion of gallium nitrate at a fixed dose of 300 mg/m2/24 hours, 40 patients were entered onto a trial lasting from September 1994 to September 1996. Eligibility included a diagnosis of an advanced malignancy not amenable to curative therapy and up to one previous chemotherapy regimen for metastatic disease. Gallium was administered at a fixed dose of 300 mg/m2/day as a continuous intravenous infusion for 120 hours. Paclitaxel starting at 90 mg/m2 was given concurrently with the last 24 hours of the gallium as a 24-hour intravenous infusion. Cycles were repeated every 21 days. Once the maximum tolerated dose (MTD) of paclitaxel was reached, G-CSF (5 microg/kg/day days 7-16) was added and paclitaxel dose escalation continued. The MTD for paclitaxel without G-CSF was 110 mg/m2 and 225 mg/m2 with G-CSF, with neutropenia being the dose-limiting toxicity. A partial response was noted in a patient who had thymoma and a complete response was achieved in a patient who had colon cancer. The recommended phase II dosage is gallium nitrate at 300 mg/m2/day over 120 hours, with pa...Continue Reading

References

Feb 1, 1991·Investigational New Drugs·A I EinzigT J Smith
Dec 18, 1991·Journal of the National Cancer Institute·F A HolmesG N Hortobagyi
Nov 6, 1991·Journal of the National Cancer Institute·P A Seligman, E D Crawford
Jun 1, 1990·Cancer·S S LeghaR S Benjamin
Apr 26, 1969·Nature·B RosenbergV H Mansour
Jan 18, 1983·Biochemistry·W R Harris, V L Pecoraro
Oct 12, 1995·The New England Journal of Medicine·K H Meyer zum Büschenfelde, A W Lohse
Oct 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B S ReichmanC A Hudis
Apr 13, 1995·The New England Journal of Medicine·E K Rowinsky, R C Donehower
Mar 3, 1993·Journal of the National Cancer Institute·W K MurphyM N Raber
Sep 1, 1996·American Journal of Respiratory Cell and Molecular Biology·N BerkmanK F Chung

❮ Previous
Next ❯

Citations

Jun 7, 2002·Critical Reviews in Oncology/hematology·Philippe ColleryBernard Desoize
Jun 17, 2005·Expert Opinion on Pharmacotherapy·Kyriakos P Papadopoulos, Charles R Thomas
Jun 19, 2017·Journal of Cancer Research and Clinical Oncology·Mukundan Baskar Mannargudi, Subrata Deb
Mar 29, 2002·Cancer·Giovannella PalmieriSecondo Lastoria
Mar 11, 2005·Expert Review of Anticancer Therapy·Robert A Huddart, Alison J Birtle

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Patrick J LoehrerEastern Cooperative Oncology Group Phase II Trial
European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery
Rajashekara H V ReddyJames A C Thorpe
© 2022 Meta ULC. All rights reserved